反应详情

The title compound was prepared from iodomethyl 2-(methyloxy)ethyl carbonate (59 mg, 0.227 mmol) (prepared in a similar manner to example 1), (4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide sodium salt (50 mg, 0.113 mmol), potassium carbonate (47 mg, 0.340 mmol), and tetrabutylammonium hydrogen sulfate (39 mg, 0.113 mmol), using a similar process to that described in example 1. 1H NMR (CDCl3) δ 10.32 (m, 1H), 8.37 (s, 1H), 7.31 (m, 1H), 6.77 (m, 2H), 5.83 (m, 2H), 5.16 (m, 1H), 4.92 (m, 1H), 4.57 (d, J=6 Hz, 2H), 4.29-4.23 (m, 3H), 4.16 (m, 1H), 3.93 (m, 2H), 3.62-3.57 (m, 2H), 3.32 (s, 3H), 2.13 (m, 1H), 1.46 (m, 1H), 1.30 (d, J=7.2 Hz, 3 H). ES+MS: 552 (M+1).